P2y(12), a new platelet ADP receptor, target of clopidogrel

Biochemical and Biophysical Research Communications
Pierre SaviJ M Herbert

Abstract

The binding characteristics of (33)P-2MeS-ADP, a stable analogue of ADP, were determined on CHO cells transfected with the human P2Y(12) receptor, a novel purinergic receptor. These transfected CHO cells displayed a strong affinity for (33)P-2MeS-ADP, the binding characteristics of which corresponded in all points to those observed on platelets. In particular, this receptor recognised purines with the following order of potency: 2MeS-ADP = 2MeS-ATP > ADP = ATPgammaS = ATP > UTP, a binding profile which is similar to that obtained in platelets. The binding of (33)P-2MeS-ADP was antagonised by pCMPS but not by MRS2179 and FSBA, antagonists of P2Y(1) and aggregin, respectively. Moreover, the binding of (33)P-2MeS-ADP to these cells was strongly and irreversibly inhibited by the active metabolite of clopidogrel with a potency which was consistent with that observed for this compound on platelets. Like in platelets, 2MeS-ADP induced adenylyl cyclase down-regulation in these P2Y(12) transfected CHO cells, an effect which was absent in the corresponding non-transfected cells. As already shown in platelets, the active metabolite of clopidogrel antagonised 2MeS-ADP-induced inhibition of adenylyl cyclase on transfected cells. Our results...Continue Reading

References

Apr 1, 1992·Arteriosclerosis and Thrombosis : a Journal of Vascular Biology·D C MillsR W Colman
Sep 8, 1980·Clinica Chimica Acta; International Journal of Clinical Chemistry·H MeursK De Vries
Sep 1, 1980·Analytical Biochemistry·P J Munson, D Rodbard
Jul 1, 1980·Proceedings of the National Academy of Sciences of the United States of America·G Urlaub, L A Chasin
Oct 15, 1994·Thrombosis Research·P SaviJ M Herbert
Nov 5, 1997·British Journal of Haematology·P SaviJ M Herbert
Mar 14, 1998·FEBS Letters·P SaviJ M Herbert
Dec 6, 2000·The Journal of Biological Chemistry·F L ZhangF J Monsma

❮ Previous
Next ❯

Citations

Apr 12, 2008·Purinergic Signalling·Luz María G CarrasqueroM Teresa Miras-Portugal
Jan 30, 2002·British Journal of Pharmacology·Robert A Kaiser, Iain L O Buxton
Jun 7, 2006·CMAJ : Canadian Medical Association Journal = Journal De L'Association Medicale Canadienne·Jung-Won SuhHyo-Soo Kim
Sep 1, 2005·Future Cardiology·Daniel C Bezerra, Julien Bogousslavky
Feb 8, 2014·Molecular Phylogenetics and Evolution·Kavita Kumari Kakarala, Kaiser Jamil
Feb 13, 2003·Proceedings of the National Academy of Sciences of the United States of America·Marco CattaneoZaverio M Ruggeri
Jul 13, 2006·Proceedings of the National Academy of Sciences of the United States of America·Pierre SaviJean-Marc Herbert
Jan 17, 2002·International Journal of Hematology·C Gachet
Jul 23, 2003·Journal of Thrombosis and Haemostasis : JTH·B HechlerK Ravid
Apr 4, 2008·European Journal of Clinical Pharmacology·Kyoung-Ah KimJi-Young Park
Jan 9, 2010·Expert Opinion on Emerging Drugs·Chiara LazzeriG F Gensini
Apr 2, 2002·Expert Opinion on Investigational Drugs·Mats ErikssonAnders Larsson
Nov 30, 2012·Journal of Pharmaceutical Sciences·Zhixia QiuXijing Chen
Jan 13, 2016·Proceedings of the National Academy of Sciences of the United States of America·Nanhong LouMaiken Nedergaard
Sep 21, 2015·American Journal of Cardiovascular Drugs : Drugs, Devices, and Other Interventions·Jean-Philippe ColletGilles Montalescot
Mar 29, 2011·Biophysical Chemistry·Haibo LiuJun Xu
Jan 26, 2010·Molecular and Cellular Neurosciences·Sony Shakya ShresthaTrevor J Bushell
Dec 3, 2009·Critical Care Nursing Clinics of North America·Dawn Meyer
Nov 1, 2015·Neuropharmacology·Ivar von Kügelgen, Kristina Hoffmann
Feb 1, 2005·Basic & Clinical Pharmacology & Toxicology·Tina Svenstrup PoulsenPer Damkier
Jan 14, 2004·Journal of Thrombosis and Haemostasis : JTH·C SouletP Savi
Jan 20, 2006·Journal of Thrombosis and Haemostasis : JTH·C OuryM F Hoylaerts
Mar 1, 2006·Pharmacotherapy·Mohammad J TafreshiElmer J Gentry
Jan 13, 2006·British Journal of Pharmacology·Anna M LewandowiczJarmo T Laitinen
Dec 20, 2007·Journal of Thrombosis and Haemostasis : JTH·J F BartonS J Mundell
Oct 12, 2013·The Journal of Pathology·Simon A SmithSimon J Hollingsworth
Dec 12, 2003·Hematology·Robert T DorsamSatya P Kunapuli
Nov 1, 2005·Pharmacology & Therapeutics·Ivar von Kügelgen
Feb 18, 2003·British Journal of Haematology·Jean O ContreresSylviane Levy-Toledano
Jul 29, 2006·Expert Opinion on Pharmacotherapy·Hussam Hamdalla, David J Moliterno
Jun 7, 2005·Expert Opinion on Pharmacotherapy·Hans-Christoph DienerPierre Savi

❮ Previous
Next ❯

Related Concepts

Trending Feeds

COVID-19

Coronaviruses encompass a large family of viruses that cause the common cold as well as more serious diseases, such as the ongoing outbreak of coronavirus disease 2019 (COVID-19; formally known as 2019-nCoV). Coronaviruses can spread from animals to humans; symptoms include fever, cough, shortness of breath, and breathing difficulties; in more severe cases, infection can lead to death. This feed covers recent research on COVID-19.

Blastomycosis

Blastomycosis fungal infections spread through inhaling Blastomyces dermatitidis spores. Discover the latest research on blastomycosis fungal infections here.

Nuclear Pore Complex in ALS/FTD

Alterations in nucleocytoplasmic transport, controlled by the nuclear pore complex, may be involved in the pathomechanism underlying multiple neurodegenerative diseases including Amyotrophic Lateral Sclerosis and Frontotemporal Dementia. Here is the latest research on the nuclear pore complex in ALS and FTD.

Applications of Molecular Barcoding

The concept of molecular barcoding is that each original DNA or RNA molecule is attached to a unique sequence barcode. Sequence reads having different barcodes represent different original molecules, while sequence reads having the same barcode are results of PCR duplication from one original molecule. Discover the latest research on molecular barcoding here.

Chronic Fatigue Syndrome

Chronic fatigue syndrome is a disease characterized by unexplained disabling fatigue; the pathology of which is incompletely understood. Discover the latest research on chronic fatigue syndrome here.

Evolution of Pluripotency

Pluripotency refers to the ability of a cell to develop into three primary germ cell layers of the embryo. This feed focuses on the mechanisms that underlie the evolution of pluripotency. Here is the latest research.

Position Effect Variegation

Position Effect Variagation occurs when a gene is inactivated due to its positioning near heterochromatic regions within a chromosome. Discover the latest research on Position Effect Variagation here.

STING Receptor Agonists

Stimulator of IFN genes (STING) are a group of transmembrane proteins that are involved in the induction of type I interferon that is important in the innate immune response. The stimulation of STING has been an active area of research in the treatment of cancer and infectious diseases. Here is the latest research on STING receptor agonists.

Microbicide

Microbicides are products that can be applied to vaginal or rectal mucosal surfaces with the goal of preventing, or at least significantly reducing, the transmission of sexually transmitted infections. Here is the latest research on microbicides.